Gland Pharma Limited — Q3 FY26 earnings call

Call held 28 Jan 2026

Management summary

Gland Pharma delivered a strong Q3 FY26, characterized by robust volume-led growth in the US and a successful EBITDA turnaround at Cenexi. While US pricing saw a 5-6% erosion, it was more than offset by a 19% volume surge and internal cost efficiencies. The company is pivoting toward high-end CDMO work, evidenced by a new $25-30 million oncology contract and significant capacity expansion in cartridges and biologics.

Highlights

  • Consolidated revenue reached ₹16,954 million, representing a 22% YoY growth.

  • Adjusted EBITDA increased 25% YoY to ₹4,490 million with a 26% margin.

  • Cenexi achieved an EBITDA turnaround, reporting a positive EBITDA of ₹148 million (EUR 1 million).

  • US revenue grew 16% YoY to ₹8,290 million, driven by a 19% increase in volumes despite pricing pressure.

  • R&D investment stood at 5.4% of revenue (₹650 million), with 9 ANDA filings and 4 approvals during the quarter.

  • Management announced a ₹2,000 crore brownfield capex plan over the next 5 years.

  • Organic growth guidance set at 15% CAGR over the next 5 years.

Key financials

  1. Revenue 16,954 Mn +22%YoY
  2. Adjusted EBITDA 4,490 Mn +25%YoY
  3. EBITDA Margin 26%
  4. Adjusted PAT 2,797 Mn
  5. R&D Spend 5.4%

What they filed

Q1 FY27: revenue up 23.9%, net profit up 35.3% against the same quarter last year.

₹ Cr · quarterly
Line itemQ2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26Q3 FY26Q4 FY26Q1 FY27
Revenue1,063 1,011 1,030 1,039 1,074 +1%1,178 +17%1,262 +23%1,287 +24%
EBITDA364 391 394 359 375 +3%422 +8%508 +29%474 +32%
Net profit282 295 290 269 302 +7%308 +4%420 +45%364 +35%
How to read this

₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.

Segment breakdown

Share of Revenue
16,954 Mn Total
  • Base Business (Gland) 11,790 Mn 69.5%
  • Cenexi 5,164 Mn 30.5%

Guidance & targets

Capex

  • Brownfield Expansion Capex Capex · next 5 years · High confidence ₹2,000 crores
    Over the next 5 years, we plan to invest approximately INR2,000 crores in capex, primarily towards BFS and ophthalmic lines as well as capex towards CDMO contracts.

    — Srinivas Sadu, Executive Chairman

Revenue

  • Organic Revenue CAGR Revenue · next 5 years · Medium confidence 15%
    So we are looking at 15% CAGR 5 years as a company, other than the inorganic what we meant to in the next few years. As organic, we look at 15% CAGR for 5 years.

    — Srinivas Sadu, Executive Chairman

  • Oncology CDMO Contract Revenue Revenue · per year starting FY28 · High confidence $25 million to $30 million
    The expected revenues are around $25 million to $30 million per year... commercialization will happen in third or fourth quarter of '28.

    — Srinivas Sadu, Executive Chairman

Capacity

  • Cartridge Fill and Finish Capacity Capacity · FY27 · High confidence 140 million units

    From 40 million units today

    Looking at the growth drivers and pipeline expansion, we are significantly expanding cartridge fill and finish capacity from 40 million to 140 million units.

    — Srinivas Sadu, Executive Chairman

Margin

  • Investment Hurdle Rate (IRR) Margin · Ongoing · High confidence 20%
    But our hurdle rate for any investment is, of course, 20% IRR. So that we keep in mind when we make our internal investment projections.

    — Ravi Mitra, CFO

Risks & concerns

  • US Generic Pricing Erosion

    medium

    Management noted a 5-6% price drop in the US, which they are countering through internal cost efficiencies and larger batch sizes.

    Management acknowledged

  • Partner Product Launch Delays

    medium

    The Dalba launch in the US by a partner has been delayed, though management expects approval soon following additional data submission.

    Analyst acknowledged

  • Capacity Underutilization

    medium

    The expansion to 140M cartridge units will only see 15-20M utilization in FY27, creating a temporary drag on ROCE.

    Both acknowledged

Areas of evasion (2)

  • Specific TAM for the 15 co-development products was deferred.
  • Exact quarterly run-rate sustainability for seasonal products like inactivated vaccines.

Q&A highlights

2 direct
Oncology CDMO Contract Details Direct
The expected revenues are around $25 million to $30 million per year... we have to create some dedicated compounding area for this product. So that's why this time, and then the tech-transfer, and then the variation filing.

Reveals the scale and timeline (FY28) for high-value complex CDMO work, which is a key part of the long-term strategy.

Asked by Tushar Manudhane

Capex Rationale and Asset Turns Direct
The asset turn should be more than around 3x. Considering the high-value business, we are expecting in this new facility.

Management justifies the ₹2,000 crore capex by projecting high asset turns (3x) from high-value ophthalmic and BFS lines.

Asked by Tarang Agrawal

GLP-1 and Cartridge Capacity Utilization Partial
Overall, looking at the things we can look at in FY '27 around 15 million to 20 million utilization. It would take some time for us to completely utilize 140 million.

Highlights a potential risk of low initial utilization (10-15%) for the massive new 140M unit cartridge capacity in the first year.

Asked by Ashish

2 min read 5 chapters

Detailed narrative

Cenexi Turnaround and Integration

Cenexi achieved a significant milestone by reaching EBITDA breakeven this quarter, reporting a positive EBITDA of ₹148 million (EUR 1 million) on revenues of EUR 50 million. This turnaround was driven by capacity debottlenecking, contract re-pricing to account for inflation, and workforce optimization. Management expects Cenexi to remain on a growth trajectory with an annualized revenue base of approximately EUR 200 million, supported by new high-speed lines and deeper operational integration with Gland's India operations.

US Market Resilience and Volume Growth

The US market remains Gland's primary growth engine, with revenue increasing 16% YoY to ₹8,290 million. While the segment faced pricing pressure of 5-6%, this was successfully offset by a 19% increase in volumes. The uptick is attributed to new GPO contracts for top products and the launch of 9 new molecules during the quarter. Management is focusing on internal efficiencies, such as increasing batch sizes and using larger capacity tanks, to maintain margins despite lower pricing.

Strategic Pivot to Complex CDMO

Gland is aggressively moving toward high-end innovation-led CDMO services. A key highlight is the securing of a new oncology CDMO contract expected to generate $25-30 million in annual revenue starting in late FY28. This project requires a dedicated ₹80 crore capex for a compounding area. The company is also expanding its pipeline into hormones, peptides, and biosimilars, moving beyond traditional B2B models to secure long-term revenue visibility.

Massive Capacity Expansion in Cartridges

The company is significantly scaling its cartridge fill and finish capacity from 40 million to 140 million units to capture the growing GLP-1 and insulin market. While the additional 100 million unit line is expected to be ready for exhibit batches by Q2 FY27, initial utilization is projected at a conservative 15-20 million units for FY27. Management emphasized that the lines are fungible, allowing them to fill vials and cartridges on the same equipment to mitigate underutilization risks.

Long-term Capex and Financial Health

Gland announced a ₹2,000 crore brownfield capex plan over the next five years, primarily targeting BFS (Blow-Fill-Seal) and ophthalmic lines where current capacity is nearly exhausted (80-90% utilization). Despite this heavy investment, the company maintains a strong balance sheet with ₹30,525 million in cash and equivalents. The investment strategy is disciplined, targeting a minimum 20% IRR and expected asset turns of 3x for the new high-value facilities.

This is an AI-generated summary of a publicly available earnings call transcript.
View original transcript

More Healthcare earnings calls